RE.GA.IN. Brings Gastritis Back Into Focus as a Clinicopathological Disease
The Real-world Gastritis Initiative, known as RE.GA.IN., is a consensus effort built to reposition gastritis as more than a vague endoscopic label. In the Gut report, the international faculty did not treat gastric inflammation as a single entity. Instead, they organized it as a spectrum of clinicopathological states with distinct causes, prognostic weight, and management consequences.
This matters because gastritis sits at the intersection of symptoms, mucosal injury, infection, autoimmunity, microbial ecology, and gastric cancer risk. A patient can look similar at the bedside while carrying very different underlying biology. The practical challenge for clinicians is not simply identifying inflammation, but deciding whether it reflects Helicobacter pylori, autoimmune injury, a broader environmental pattern, or a condition that should be staged histologically for long-term risk assessment.
The Venice consensus process, completed in November 2022 after more than eight months of international deliberation, brought together gastritis experts from five continents. The goal was straightforward and ambitious at once: distill evidence into patient-centered statements that can be used in routine care rather than in an academic vacuum.
Helicobacter pylori Remains the Dominant Environmental Driver
Among the themes addressed, Helicobacter pylori remains central. The consensus places the organism not only as the dominant cause of environmental gastritis, but also as the key determinant of the gastric oncogenetic field. In clinical terms, that means the bacterium is not merely a trigger for inflammation; it helps shape the biological terrain in which atrophy, metaplasia, dysplasia, and ultimately cancer may emerge.
That framing carries real bedside consequences. A biopsy showing chronic active gastritis is not the end of the diagnostic process if the pattern fits H pylori-associated disease. Infection should be considered in the context of broader mucosal injury and future risk, because chronic inflammation can continue to alter the gastric microenvironment long after symptoms have faded. The consensus therefore reinforces a familiar but still underused principle: the aetiology of gastritis matters as much as the presence of inflammation itself.
One sentence captures the clinical pivot: gastritis is not one diagnosis.
Autoimmunity, Microbiota, and the Expanding Differential Diagnosis
The consensus also addresses evolving knowledge on gastric autoimmunity. Autoimmune gastritis occupies a different biological space from infectious disease, with distinct consequences for mucosal architecture and long-term surveillance. Recognizing that distinction helps avoid treating all gastritis as if the same inflammatory mechanism were operating. The histologic pattern, distribution of injury, and associated clinical clues steer the workup toward the correct pathway.
Equally important is the discussion of the gastric microbiota. The stomach was once considered too hostile for meaningful microbial ecology, but that view has given way to a more complex understanding. Changes in the gastric microbial environment may interact with inflammation, acid suppression, tissue injury, and carcinogenic progression. The consensus does not reduce this area to a single biomarker or a ready-made therapeutic target. Instead, it acknowledges that microbial composition belongs inside the modern explanation of gastritis rather than at its margins.
That shift broadens the clinician’s mental model. Gastritis can no longer be approached solely through the lens of acid injury or a binary infected-versus-uninfected framework. The stomach behaves like a biologic ecosystem, and inflammation often reflects disturbance across several layers at once.
Endoscopy Is Useful, but Histology Still Carries the Long Game
The report gives attention to the new diagnostic horizons of endoscopy, yet the emphasis remains grounded in pathology. Endoscopic assessment can reveal visible mucosal abnormalities, direct biopsy sampling, and help identify patterns that warrant closer inspection. Still, visual impression alone does not stage gastritis or define its prognostic importance. The tissue diagnosis remains the anchor.
This is where histology becomes clinically decisive. RE.GA.IN. places special weight on staging gastritis histologically, because staging converts a descriptive biopsy into a prognostic tool. Inflammation, atrophy, and related structural changes can be organized in a way that informs future risk rather than simply documenting present injury. For clinicians, that approach is especially useful when symptoms are nonspecific or when endoscopic findings do not fully reflect underlying disease burden.
A biopsy that reports gastritis without staging leaves too much unsaid.
By contrast, structured histologic reporting can clarify where a patient sits in the disease spectrum and whether the mucosa has already entered a higher-risk state. The consensus treats this as a priority because real-world management depends on more than symptom control. It depends on anticipating who needs treatment, who needs surveillance, and who needs risk reduction centered on the underlying cause.
Epidemiology and Prognosis Shape the Clinical Framing
The sections on epidemiology and prognosis reinforce a broad but important point: gastritis is common, heterogeneous, and clinically consequential. The paper presents gastritis as a disorder whose meaning depends on its cause, distribution, and structural footprint. A generic label may be convenient, but it is not enough for long-term planning.
In practice, prognosis hinges on whether the inflammatory process is transient, persistent, or tied to a carcinogenic pathway. The consensus therefore links the diagnostic process to future outcomes. That linkage is especially relevant in settings where H pylori remains prevalent and where environmental gastritis continues to account for a large share of disease burden. In those contexts, the clinician’s task includes identifying the agent, assessing the mucosa, and interpreting the result through a cancer-prevention lens.
The report does not present gastritis as a settled topic. It presents it as a field that has matured enough to support more precise, biologically informed decisions.
A Consensus Built for Real-World Practice
RE.GA.IN. is framed as a real-world initiative rather than a purely academic exercise, and that orientation shapes the tone of the consensus. The faculty assembled complementary expertise, debated controversial aspects of the gastritis spectrum, and converted those discussions into statements designed for routine use. The result is a clinical framework that connects cause, pathology, diagnostic approach, and prognostic staging.
For gastroenterologists, pathologists, and endoscopists, the message is direct. Gastritis should be defined with greater precision, assigned to the correct etiologic category whenever possible, and staged in a way that reflects future risk. Helicobacter pylori remains the most important environmental driver, gastric autoimmunity demands separate recognition, and histologic reporting retains a central role in decision-making.
The unresolved challenge is implementation. Consensus statements can clarify the science, but their value depends on whether routine pathology reports, endoscopic practice, and infection management actually follow the same logic at the bedside.